Chan Lee - BeiGene G Counsel
| B1GN34 Stock | BRL 42.30 1.46 3.34% |
Insider
Chan Lee is G Counsel of BeiGene
| Phone | 781-801-1800 |
| Web | https://www.beigene.com |
Chan Lee Latest Insider Activity
Tracking and analyzing the buying and selling activities of Chan Lee against BeiGene stock is an integral part of due diligence when investing in BeiGene. Chan Lee insider activity provides valuable insight into whether BeiGene is net buyers or sellers over its current business cycle. Note, BeiGene insiders must abide by specific rules, including filing SEC forms every time they buy or sell BeiGene'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Chan Lee over two months ago Disposition of 1202 shares by Chan Lee of BeiGene at 237.1 subject to Rule 16b-3 | ||
Chan Lee over three months ago Disposition of 834 shares by Chan Lee of BeiGene at 160.57 subject to Rule 16b-3 |
BeiGene Management Efficiency
The company has return on total asset (ROA) of (0.1971) % which means that it has lost $0.1971 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5254) %, meaning that it generated substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sean Marett | BIONTECH SE DRN | 58 | |
| Lotte Sonderbjerg | Ascendis Pharma AS | 62 | |
| MD FASN | Vertex Pharmaceuticals Incorpor | 50 | |
| Ourania Tatsis | Vertex Pharmaceuticals Incorpor | 52 | |
| Susie Lisa | Vertex Pharmaceuticals Incorpor | N/A | |
| Sangeeta Bhatia | Vertex Pharmaceuticals Incorpor | 50 | |
| Terrence Kearney | Vertex Pharmaceuticals Incorpor | 64 | |
| Noubar Afeyan | Moderna | 60 | |
| Bruce Sachs | Vertex Pharmaceuticals Incorpor | 58 | |
| Jerh Collins | Moderna | N/A | |
| John Gray | Vertex Pharmaceuticals Incorpor | 53 | |
| James Mock | Moderna | 46 | |
| Michael Boehler | BIONTECH SE DRN | N/A | |
| Kennett Sprogoe | Ascendis Pharma AS | 44 | |
| William Young | Vertex Pharmaceuticals Incorpor | 74 | |
| Damian Esq | Vertex Pharmaceuticals Incorpor | 47 | |
| Heraldo Marchezini | Biomm SA | N/A | |
| Stuart Arbuckle | Vertex Pharmaceuticals Incorpor | 53 | |
| Jens Holstein | BIONTECH SE DRN | 60 | |
| David Altshuler | Vertex Pharmaceuticals Incorpor | 53 | |
| Stephen MD | Moderna | 47 | |
Management Performance
| Return On Equity | -0.53 | |||
| Return On Asset | -0.2 |
BeiGene Leadership Team
Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Oyler, Ex CoFounder | ||
| Xiaodong Wang, Chairman CoFounder | ||
| Mi Zhou, Director Relations | ||
| Daniel Maller, VP Accounting | ||
| Chan Lee, G Counsel | ||
| Wang Lai, Global RD | ||
| Kevin Mannix, VP Relations | ||
| Diana Francis, VP Compliance | ||
| Julia Wang, CFO Officer | ||
| Xiaobin Wu, COO Pres |
BeiGene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BeiGene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.53 | |||
| Return On Asset | -0.2 | |||
| Profit Margin | (1.68) % | |||
| Operating Margin | (1.52) % | |||
| Current Valuation | 93.43 B | |||
| Shares Outstanding | 1.35 B | |||
| Price To Book | 2.09 X | |||
| Price To Sales | 92.86 X | |||
| Revenue | 1.18 B | |||
| Gross Profit | (447.86 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in BeiGene Stock
When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.